Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Weekly Wrap 20 September

Bell Direct
September 20, 2024

Morning Bell 19 September

Bell Direct
September 19, 2024

Morning Bell 18 September

Bell Direct
September 18, 2024

Morning Bell 17 September

Bell Direct
September 17, 2024

Morning Bell 16 September

Bell Direct
September 16, 2024

Weekly Wrap 13 September

Bell Direct
September 13, 2024

Morning Bell 13 September

Bell Direct
September 13, 2024

Morning Bell 12 September

Bell Direct
September 12, 2024

8 minutes with 8 executives

Bell Direct
September 11, 2024

Morning Bell 11 September

Bell Direct
September 11, 2024

Morning Bell 10 September

Bell Direct
September 10, 2024

Morning Bell 9 September

Bell Direct
September 9, 2024